Highest quality, information-rich data - select and develop the best possible biotherapeutics
•
Rapid selection of candidates - e.g. primary screening of monoclonal antibodies direct from hybridomas
•
Better-informed selection and development - detailed characterization of binding properties relevant for therapeutic efficacy
•
Improved safety of protein-based therapeutics - manufacturing QC and immunogenicity studies
Biotherapeutics may take the form of antibodies, antibody fragments or other recombinant proteins. Biacore systems offer a unique level of characterization to facilitate the selection process. Interactions can be fully characterized within days.
Regulatory authorities place high demands on safety during biotherapeutic development and manufacturing processes. Biacore systems offer unique detection and characterization of unwanted immune responses to therapeutic agents, direct from serum samples, and provides a range QC assays during manufacturing.
"Biacore provides the best available analysis of affinity and binding kinetics for our protein therapeutic candidates" Peter Flynn PhD, Director, Biochemistry Research, KaloBios Pharmaceuticals Inc, Palo Alto, California, USA.
Choose your destination
